BNTC8:00 AMBenitec Biopharma Releases Third Quarter 2026 Financial Results and Provides Operational UpdatePresentation / Abstract • Phase 1ASGCT oral presentation Fri, May 15, 2026, 8:00 AM EDTGbenitec.com
BNTC7:00 AMBenitec Biopharma Announces Oral Presentation of Interim Phase 1b/2a Clinical Study Results for High Dose BB-301 and Continued Durable Improvements for Low Dose BB-301 at the 2026 American Society of Gene and Cell Therapy Annual MeetingPresentation / Abstract • Phase 1/2benitec.com